Cardioprotection by ranolazine in perfused rat heart

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 6, 2014, Pages 507-513

  Ghelardoni, Sandra ^a   Chiellini, Grazia ^a   Frascarelli, Sabina ^a   Zucchi, Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Calcium; Cardioprotection; Ischemia; Ranolazine; Reperfusion

Indexed keywords

CALCIUM; OXYGEN; RANOLAZINE; RYANODINE; TRIPHENYLTETRAZOLIUM; ACETANILIDE DERIVATIVE; CARDIOTONIC AGENT; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA PRESSURE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG BINDING SITE; DRUG HALF LIFE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART PERFUSION; HEART PROTECTION; HEART RATE; ISOLATED HEART; MALE; NONHUMAN; RAT; RAT MODEL; REPERFUSION INJURY; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MYOCARDIAL REPERFUSION INJURY; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; SARCOPLASMIC RETICULUM; WISTAR RAT;

ACETANILIDES; ANIMALS; CALCIUM; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MYOCARDIAL REPERFUSION INJURY; OXYGEN CONSUMPTION; PIPERAZINES; RATS; RATS, WISTAR; RYANODINE; SARCOPLASMIC RETICULUM;

EID: 84918582499     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000144     Document Type: Article

References (41)

1. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina in patients with severe chronic angina: A randomized controlled trial. JAMA. 2004;291:309-316.
2. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375-1382.
3. Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48: 566-575.
4. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: The Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007;49: 1027-1034.
5. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775-1783.
6. Allely MC, Alps BJ. Prevention of myocardial enzyme release by ranolazine in a primate model of ischemia with reperfusion. Br J Pharmacol. 1990;99:5-6.
7. Clarke B, Spedding M, Patmore L, et al. Protective effects of ranolazine in guinea-pig hearts during low-flow ischemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol. 1993;109: 748-750.
8. Gralinski MR, Black SC, Kilgore KS, et al. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 1994;28:1231-1237.
9. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin t release in the rat. Eur J Pharmacol. 2001;418: 105-110.
10. Hale SL, Leeka JA, Kloner RA. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. J Pharmacol Exp Ther. 2006;318:418-423.
11. Aldakkak M, Camara AK, Heisner JS, et al. Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol Res. 2011;64:381-392.
12. Black SC, Gralinski MR, McCormack JG, et al. Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion. J Cardiovasc Pharmacol. 1994;24:921-928.
13. Pelliccia F, Pasceri V, Marazzi G, et al. A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. Am Heart J. 2012;163:1019-1023.
14. Venkataraman R, Chen J, Garcia EV, et al. Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease. Am J Cardiol. 2012;110:1440-1445.
15. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904-910.
16. Shryrock JC, Belandinelli L. Inibition of the late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br J Pharmacol. 2008;153:1133-1142.
17. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac late sodium current. Pharmacol Ther. 2008;119: 326-339.
18. Zucchi R, Ghelardoni S, Evangelista E. Biochemical basis of ischemic heart injury and of cardioprotective interventions. Curr Med Chem. 2007; 14:1619-1637.
19. Schaub RG, Stewart G, Strong M, et al. Reduction of ischemic myocardial damage in the dog by lidocaine infusion. Am J Pathol. 1977;87: 399-414.
20. Ebel D, Lipfert P, Fraessdorf J, et al. Lidocaine reduces ischaemic but not reperfusion injury in isolated rat heart. Br J Anaesth. 2001;86:846-852.
21. Granfeldt A, Nielsen TK, Solling C, et al. Adenocaine and Mg2+ reduce fluid requirement to maintain hypotensive resuscitation and improve cardiac and renal function in a porcine model of severe hemorrhagic shock. Crit Care Med. 2012;40:3013-3025.
22. Stone PH, Chaitman BR, Stocke K, et al. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol. 2010;56:934-942.
23. McCormack JG, Barr RL, Wolff AA, et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic and reperfused ischemic rat hearts. Circulation. 1996;93:135-142.
24. Wang P, Fraser H, Lloyd SG, et al. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther. 2007;321: 213-220.
25. Zucchi R, Ronca F, Ronca-Testoni S. Modulation of sarcoplasmic reticulum function: A new strategy in cardioprotection? Pharmacol Ther. 2001;89:47-65.
26. Parikh A, Mantravadi R, Kozhevnikov D, et al. Ranolazine stabilizes cardiac ryanodine receptors: A novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. Heart Rhythm. 2012;9:953-960.
27. Sossalla S, Wagner S, Rasenack EC, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol. 2008;45:32-43.
28. Zucchi R, Ghelardoni S, Carnicelli V, et al. Ca2+ channel remodeling in perfused heart: effects of mechanical work and interventions affecting Ca2+ cycling on sarcolemmal and sarcoplasmic reticulum Ca2+ channels. FASEB J. 2002;16:1976-1978.
29. Zucchi R, Limbruno U, Poddighe R, et al. Purine release from isolated rat heart: A new approach to the study of energy metabolism. J Mol Cell Cardiol. 1990;22:815-826.
30. Zucchi R, Ronca-Testoni S, Yu G, et al. Postischemic changes in cardiac sarcoplasmic reticulum Ca2+ channels: A possible mechanism of ischemic preconditioning. Circ Res. 1995;76:1049-1056.
31. Zucchi R, Ronca-Testoni S, Yu G, et al. Effect of ischemia and reperfusion on cardiac ryanodine receptors-sarcoplasmic reticulum Ca2+ channels. Circ Res. 1994;74:271-280.
32. Ghelardoni S, Suffredini S, Frascarelli S, et al. Modulation of cardiac ionic homeostasis by 3-iodothyronamine. J Cell Mol Med. 2009;13: 3082-3090.
33. Keating GM. Ranolazine: A review of its use in chronic stable angina pectoris. Drugs. 2008;68:2483-2503.
34. Wasserstrom JA, Sharma R, O'Toole MJ, et al. Ranolazine antagonizes the effects of increased late sodium current on intracellular calcium cycling in rat isolated intact heart. J Pharmacol Exp Ther. 2009;331: 382-391.
35. Fredj S, Sampson KJ, Liu K, et al. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. 2006;148:16-24.
36. Zucchi R, Ronca-Testoni S. The sarcoplasmic reticulum Ca2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev. 1997;49:1-51.
37. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415: 198-205.
38. Bers DM. Macromolecular complexes regulating cardiac ryanodine receptor function. J Mol Cell Cardiol. 2004;37:417-429.
39. Lindegger N, Hagen BM, Marks AR, et al. Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine. J Mol Cell Cardiol. 2009;47:326-334.
40. Yu G, Zucchi R, Ronca-Testoni S, et al. Protection of ischemic rat heart by dantrolene, an antagonist of the sarcoplasmic reticulum calcium release channel. Basic Res Cardiol. 2000;95:137-143.
41. Gauthier LD, Greenstein JL, Winslow RL. Toward an integrative computational model of the guinea pig cardiac myocyte. Front Physiol. 2012;3:244.